Lara Nonell

Lara Nonell

Auto-generated profile, based on publicly available information

Lara Nonell

Bioinformatics Unit, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2025 in Cancer Research
Verified
Journal Article
Closed access
FPFlaminia Pedretti
Flaminia Pedretti
Mohamed Abdel-FattahMohamed Abdel-Fattah
Mohamed Abdel-Fattah
BPBenedetta Pellegrino
Benedetta Pellegrino
FMFrancesca Mateo
Francesca Mateo
PSPaula Martinez Sanz
Paula Martinez Sanz
VSVioleta Serra
Violeta Serra
Homologous recombination deficiency (HRD) contributes to genomic instability and leads to sensitivity to PARP inhibitors (PARPi). HRD also activates the cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING)–interferon pathway, highlighting the need to understand the impact of cGAS–STING–IFN signaling on PARPi efficacy. In this study, we analyzed a cohort of 35 breast cancer patient-derived xenografts and mouse-derived allografts. PARPi sensitivity correlated with HRD, increased genomic instability, and activation of the cGAS–STING–IFN signaling pathway. Single-cell analyses showed that IFN signaling and IFN-based immune interactions were suppressed in preclinical models with acquired resistance to PARPi, lacking concomitant clonal expansion of functional CD8+ T cells. However, the combination of a PARPi and a novel STING agonist (STINGa) increased immune infiltration and resulted in superior antitumor activity in these tumors. Notably, the efficacy of PARPi monotherapy and the combination treatment with a STINGa was dependent on natural killer (NK) cells. In agreement, patients with breast cancer with BRCA1/BRCA2 mutations and good responses to PARPi showed higher abundancy of CD56+ NK cells in the tumor microenvironment and treatment-engaged CD56bright NK cells in the peripheral immune compartment, compared with those with poor responses. Therefore, these findings propose the combination of PARPis and a STINGa as a potential novel strategy to enhance the therapeutic response in patients with acquired PARPi resistance and highlight a pivotal role of NK cells in the PARPi antitumor activity. Significance: PARP inhibitor sensitivity is associated with cGAS–STING–IFN signaling, which can be harnessed by combining PARP inhibitors with STING agonists to overcome acquired resistance and requires NK cells to mediate antitumor immunity. See related commentary by Gohari et al., p. 1747

25 April 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
OCOsmel Companioni
Osmel Companioni
JSJosé Miguel Sanz-Anquela
José Miguel Sanz-Anquela
MPMaría Luisa Pardo
María Luisa Pardo
EPEulàlia Puigdecanet
Eulàlia Puigdecanet
LNLara Nonell
Lara Nonell
NSNúria Sala
Núria Sala
Intestinal metaplasia (IM) is a precursor lesion that precedes gastric cancer (GC). There are two IM histological subtypes, complete (CIM) and incomplete (IIM), the latter having higher progression rates to GC. This study was aimed at analysing gene expression and molecular processes involved in the progression from normal mucosa to IM, and also from IM subtypes to GC. We used expression data to compare the transcriptome of healthy gastric mucosa to that of IM not progressing to GC, and the transcriptome of IM subtypes that had progressed to GC to those that did not progress. Some deregulated genes were validated and pathway analyses were performed. Comparison of IM subtypes that had progressed to GC with those that did not progress showed smaller differences in the expression profiles than the comparison of IM that did not progress with healthy mucosa. New transcripts identified in IM not progressing to GC included TRIM, TMEM, homeobox and transporter genes and SNORD116. Comparison to normal mucosa identified non tumoral Warburg effect and melatonin degradation as previously unreported processes involved in IM. Overexpressed antigen processing is common to both IM-subtypes progressing to GC, but IIM showed more over-expressed oncogenic genes and molecular processes than CIM. There are greater differences in gene expression and molecular processes involved in the progression from normal healthy mucosa to IM than from IM to gastric cancer. While antigen processing is common in both IM-subtypes progressing to GC, more oncogenic processes are observed in the progression of IIM.

11 July 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
JMJordi Martínez-Quintanilla
Jordi Martínez-Quintanilla
DCDébora Cabot
Débora Cabot
DSDoménico Sabia
Doménico Sabia
OAOriol Arqués
Oriol Arqués
FGfor the PMPnet Group
for the PMPnet Group
MMMcAllister Milly
McAllister Milly
Purpose: Pseudomyxoma peritonei (PMP) is a rare and poorly understood malignant condition characterized by the accumulation of intra-abdominal mucin produced from peritoneal metastases. Currently, cytoreductive surgery remains the mainstay of treatment but disease recurrence and death after relapse frequently occur in patients with PMP. New therapeutic strategies are therefore urgently needed for these patients. Experimental Design: A total of 120 PMP samples from 50 patients were processed to generate a collection of 50 patient-derived organoid (PDO) and xenograft (PDX) models. Whole exome sequencing, immunohistochemistry analyses, and in vitro and in vivo drug efficacy studies were performed. Results: In this study, we have generated a collection of PMP preclinical models and identified druggable targets, including BRAFV600E, KRASG12C, and KRASG12D, that could also be detected in intra-abdominal mucin biopsies of patients with PMP using droplet digital PCR. Preclinical models preserved the histopathological markers from the original patient sample. The BRAFV600E inhibitor encorafenib reduced cell viability of BRAFV600E PMP-PDO models. Proof-of-concept in vivo experiments showed that a systemic treatment with encorafenib significantly reduced tumor growth and prolonged survival in subcutaneous and orthotopic BRAFV600E-PMP-PDX mouse models. Conclusions: Our study demonstrates for the first time that systemic targeted therapies can effectively control PMP tumors. BRAF signaling pathway inhibition represents a new therapeutic opportunity for patients with BRAFV600E PMP who have a poor prognosis. Importantly, our present data and collection of preclinical models pave the way for evaluating the efficacy of other systemic targeted therapies toward extending the promise of precision oncology to patients with PMP.

1 April 2023 in Genes & Development
Verified
Journal Article
Open access
PDF file
MZMariano F. Zacarías-Fluck
Mariano F. Zacarías-Fluck
DMDaniel Massó-Vallés
Daniel Massó-Vallés
FGFabio Giuntini
Fabio Giuntini
ÍGÍñigo González-Larreategui
Íñigo González-Larreategui
JKJastrinjan Kaur
Jastrinjan Kaur
LSLaura Soucek
Laura Soucek
MYC's key role in oncogenesis and tumor progression has long been established for most human cancers. In melanoma, its deregulated activity by amplification of 8q24 chromosome or by upstream signaling coming from activating mutations in the RAS/RAF/MAPK pathway—the most predominantly mutated pathway in this disease—turns MYC into not only a driver but also a facilitator of melanoma progression, with documented effects leading to an aggressive clinical course and resistance to targeted therapy. Here, by making use of Omomyc, the most characterized MYC inhibitor to date that has just successfully completed a phase I clinical trial, we show for the first time that MYC inhibition in melanoma induces remarkable transcriptional modulation, resulting in severely compromised tumor growth and a clear abrogation of metastatic capacity independently of the driver mutation. By reducing MYC's transcriptional footprint in melanoma, Omomyc elicits gene expression profiles remarkably similar to those of patients with good prognosis, underlining the therapeutic potential that such an approach could eventually have in the clinic in this dismal disease.

4 August 2022 in BioFactors
Verified
Journal Article
Closed access
EAEvelyn Andrades
Evelyn Andrades
MCMiquel Clarós
Miquel Clarós
JTJuan Vicente Torres
Juan Vicente Torres
LNLara Nonell
Lara Nonell
MGMónica González
Mónica González
AGAna M. M Giménez-Arnau
Ana M. M Giménez-Arnau

7 January 2021 in Experimental Hematology
Verified
Journal Article
Open access
GBGonzalo Blanco
Gonzalo Blanco
APAnna Puiggros
Anna Puiggros
BSBarbara Sherry
Barbara Sherry
LNLara Nonell
Lara Nonell
Xavier CalvoXavier Calvo
Xavier Calvo
BEBlanca Espinet
Blanca Espinet
Several studies in chronic lymphocytic leukemia (CLL) patients have reported impaired immune cell functions, which contribute to tumor evasion and disease progression. However, studies on CLL-like monoclonal B-cell lymphocytosis (MBL) are scarce. In the study described here, we characterized the immune environment in 62 individuals with clinical MBL, 56 patients with early-stage CLL, and 31 healthy controls. Gene expression arrays and quantitative reverse transcription polymerase chain reaction were performed on RNA from CD4+ peripheral blood cells; serum cytokines were measured with immunoassays; and HLA-DR expression on circulating monocytes, as well as the percentages of Th1, cytotoxic, exhausted, and effector CD4+ T cells, were evaluated by flow cytometry. In addition, cell cultures of clonal B cells and CD14-enriched or -depleted cell fractions were performed. Strikingly, MBL and early-stage CLL differed in pro-inflammatory signatures. An increased inflammatory drive orchestrated mainly by monocytes was identified in MBL, which exhibited enhanced phagocytosis, pattern recognition receptors, interleukin-8 (IL8), HMGB1, and acute response signaling pathways and increased pro-inflammatory cytokines (in particular IL8, interferon γ [IFNγ], and tumor necrosis factor α). This inflammatory signature was diminished in early-stage CLL (reduced IL8 and IFNγ levels, IL8 signaling pathway, and monocytic HLA-DR expression compared with MBL), especially in those patients with mutations in IGHV genes. Additionally, CD4+ T cells of MBL and early-stage CLL exhibited a similar upregulation of Th1 and cytotoxic genes and expanded CXCR3+ and perforin+ CD4+ T cells, as well as PD1+ CD4+ T cells, compared with controls. Cell culture assays disclosed tumor-supporting effects of monocytes similarly observed in MBL and early-stage CLL. These novel findings reveal differences in the inflammatory environment between MBL and CLL, highlighting an active role for antigen stimulation in the very early stages of the disease, potentially related to malignant B-cell transformation.